Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, has published the results of the Phase II...
-
Immunicum AB (publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på behandlingar mot tumörrecidiv och svårbehandlade etablerade tumörer, tillkännagav idag sitt deltagande i följande konferenser: ...
-
Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following...
-
Immunicum AB (“Immunicum” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på behandlingar mot tumörrecidiv och svårbehandlade etablerade tumörer, meddelar idag att årsredovisningen för 2021 nu...
-
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that its Annual Report for...
-
Immunicum AB (“Immunicum” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på behandlingar mot tumörrecidiv och svårbehandlade etablerade tumörer, tillkännagav idag att företaget kommer att delta i...
-
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that the company will...
-
Pressmeddelande Stockholm, 8 april 2022 KALLELSE TILL ÅRSSTÄMMA I IMMUNICUM AB (PUBL) Aktieägarna i Immunicum AB (publ) (”Bolaget”), org.nr 556629-1786, kallas härmed till årsstämma...
-
Press Release Stockholm, Sweden, April 8, 2022 NOTICE OF ANNUAL GENERAL MEETING IN IMMUNICUM AB (PUBL) The shareholders of Immunicum AB (publ) (the “Company”), reg. no...
-
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on tumor recurrence and hard-to-treat established tumors, today announced that on Monday, 14 March it will host an...